NASDAQ:VXRT

Vaxart Stock Forecast, Price & News

$7.14

+0.18 (+2.59 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$6.87

Now: $7.14▼

$7.23

50-Day Range

$5.71

MA: $6.94▼

$7.80

52-Week Range

$0.45

Now: $7.14▼

$17.49

Volume5.04 million shs

Average Volume5.75 million shs

Market Capitalization$781.61 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.11

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. Vaxart, Inc. is headquartered in South San Francisco, California.

MarketRank^™

Overall MarketRank^™

1.33 out of 5 stars

Medical Sector

658th out of 1,923 stocks

Biological Products, Except Diagnostic Industry

87th out of 177 stocks

3.5 Analyst's Opinion

Consensus Rating
Vaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.50, Vaxart has a forecasted upside of 173.1% from its current price of $7.14.
Amount of Analyst Coverage
Vaxart has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Vaxart has received 295 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Vaxart has received 290 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Vaxart has received 50.43% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Vaxart and other stocks. Vote “Outperform” if you believe VXRT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VXRT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Vaxart does not currently pay a dividend.
Dividend Growth
Vaxart does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vaxart insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,106,671.00 in company stock.
Percentage Held by Insiders
Only 7.30% of the stock of Vaxart is held by insiders.
Percentage Held by Institutions
Only 17.90% of the stock of Vaxart is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Vaxart are expected to grow in the coming year, from ($0.35) to ($0.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vaxart is -12.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vaxart is -12.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vaxart has a P/B Ratio of 26.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VXRT

Previous SymbolNASDAQ:NABI

CUSIPN/A

CIK72444

Webwww.vaxart.com

Phone(650) 550-3500

Employees30

Debt

Debt-to-Equity RatioN/A

Current Ratio3.98

Quick Ratio3.98

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$9.86 million

Price / Sales79.27

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.27 per share

Price / Book26.44

Profitability

EPS (Most Recent Fiscal Year)($0.86)

Net Income$-18,650,000.00

Net Margins-281.50%

Return on Equity-84.90%

Return on Assets-44.67%

Miscellaneous

Outstanding Shares109,469,000

Market Cap$781.61 million

Next Earnings Date3/18/2021 (Estimated)

OptionableNot Optionable

$7.14

+0.18 (+2.59 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.

Vaxart (NASDAQ:VXRT) Frequently Asked Questions

How has Vaxart's stock been impacted by COVID-19 (Coronavirus)?

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VXRT shares have increased by 244.9% and is now trading at $7.14.
View which stocks have been most impacted by COVID-19.

Is Vaxart a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vaxart stock.
View analyst ratings for Vaxart or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Vaxart?

Wall Street analysts have given Vaxart a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vaxart wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Vaxart's next earnings date?

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Vaxart.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) announced its quarterly earnings data on Thursday, November, 12th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The biotechnology company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $1.60 million. Vaxart had a negative net margin of 281.50% and a negative trailing twelve-month return on equity of 84.90%.
View Vaxart's earnings history.

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart's stock reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for VXRT?

2 brokers have issued 12 month price targets for Vaxart's shares. Their forecasts range from $17.00 to $22.00. On average, they expect Vaxart's stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 173.1% from the stock's current price.
View analysts' price targets for Vaxart or view Wall Street analyst' top-rated stocks.

Who are some of Vaxart's key competitors?

Some companies that are related to Vaxart include bluebird bio (BLUE), Revolution Medicines (RVMD), AlloVir (ALVR), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Bavarian Nordic A/S (BVNRY), Replimune Group (REPL), Scholar Rock (SRRK), NantKwest (NK), Vericel (VCEL), Translate Bio (TBIO), C4 Therapeutics (CCCC), BioCryst Pharmaceuticals (BCRX), REGENXBIO (RGNX) and Forma Therapeutics (FMTX).
View all of VXRT's competitors.

What other stocks do shareholders of Vaxart own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), OrganiGram (OGI) and Novan (NOVN).

Who are Vaxart's key executives?

Vaxart's management team includes the following people:

Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 52, Pay $353.37k)
Ms. Margaret A. Echerd, VP, Corp. Controller & Principal Accounting Officer (Age 61, Pay $290.18k)
Mr. Cezar Andrei Floroiu M.B.A., CEO, Pres, Principal Financial Officer & Director (Age 47)
Ms. Shaily Jaini Garg, Sr. VP of Clinical Devel. & Project Management
Mr. Brant Biehn, Sr. VP of Commercial Operations
Dr. Richard M. Schwartz, Sr. VP of Technical Operations
Mr. John M. Harland M.B.A., CPA, Consultant (Age 68)

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a variety of institutional and retail investors. Top institutional investors include Strategic Wealth Management Group LLC (0.09%) and Pacer Advisors Inc. (0.02%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart.

Which institutional investors are selling Vaxart stock?

VXRT stock was sold by a variety of institutional investors in the last quarter, including Strategic Wealth Management Group LLC. Company insiders that have sold Vaxart company stock in the last year include Armistice Capital, Llc, Todd C Davis, and Wouter Latour.
View insider buying and selling activity for Vaxart or view top insider-selling stocks.

Which institutional investors are buying Vaxart stock?

VXRT stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart or or view top insider-buying stocks.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $7.14.

How big of a company is Vaxart?

Vaxart has a market capitalization of $781.61 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 30 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is www.vaxart.com.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at (650) 550-3500 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here